• Something wrong with this record ?

Ghrelin receptor antagonism of fentanyl-induced conditioned place preference, intravenous self-administration, and dopamine release in the nucleus accumbens in rats

M. Sustkova-Fiserova, N. Puskina, T. Havlickova, M. Lapka, K. Syslova, V. Pohorala, C. Charalambous

. 2020 ; 25 (6) : e12845. [pub] 20191106

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026430

The extended occurrence of fentanils abuse associated with the dramatic increase in opioid fatal overdoses and dependence strongly emphasizes insufficiencies in opioid addiction treatment. Recently, the growth hormone secretagogue receptor (GHS-R1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in opioid abuse is still unclear. Therefore, the aim of our study was to clarify whether the GHS-R1A antagonist JMV2959 could reduce the fentanyl-induced conditioned place preference (CPP), the fentanyl intravenous self-administration (IVSA), and the tendency to relapse, but also whether JMV2959 could significantly influence the fentanyl-induced dopamine efflux in the nucleus accumbens (NAC) in rats, that importantly participates in opioids' reinforcing effects. Following an ongoing fentanyl self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 minutes before three consequent daily 360-minute IVSA sessions under a fixed ratio FR1, which significantly reduced the number of active lever-pressing, the number of infusions, and the fentanyl intake. Pretreatment with JMV2959 also reduced the fentanyl-seeking/relapse-like behaviour tested in rats on the 12th day of the forced abstinence period. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of fentanyl-CPP. The fentanyl-CPP development was reduced after the simultaneous administration of JMV2959 with fentanyl during conditioning. The JMV2959 significantly reduced the accumbens dopamine release induced by subcutaneous and intravenous fentanyl. Simultaneously, it affected the concentration of byproducts associated with dopamine metabolism in the NAC. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of fentanyl.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026430
003      
CZ-PrNML
005      
20211026132917.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/adb.12845 $2 doi
035    __
$a (PubMed)31696597
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sustkova-Fiserova, Magdalena $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Czech Republic
245    10
$a Ghrelin receptor antagonism of fentanyl-induced conditioned place preference, intravenous self-administration, and dopamine release in the nucleus accumbens in rats / $c M. Sustkova-Fiserova, N. Puskina, T. Havlickova, M. Lapka, K. Syslova, V. Pohorala, C. Charalambous
520    9_
$a The extended occurrence of fentanils abuse associated with the dramatic increase in opioid fatal overdoses and dependence strongly emphasizes insufficiencies in opioid addiction treatment. Recently, the growth hormone secretagogue receptor (GHS-R1A) antagonism was proposed as a promising mechanism for drug addiction therapy. However, the role of GHS-R1A and its endogenous ligand ghrelin in opioid abuse is still unclear. Therefore, the aim of our study was to clarify whether the GHS-R1A antagonist JMV2959 could reduce the fentanyl-induced conditioned place preference (CPP), the fentanyl intravenous self-administration (IVSA), and the tendency to relapse, but also whether JMV2959 could significantly influence the fentanyl-induced dopamine efflux in the nucleus accumbens (NAC) in rats, that importantly participates in opioids' reinforcing effects. Following an ongoing fentanyl self-administration, JMV2959 3 mg/kg was administered intraperitoneally 20 minutes before three consequent daily 360-minute IVSA sessions under a fixed ratio FR1, which significantly reduced the number of active lever-pressing, the number of infusions, and the fentanyl intake. Pretreatment with JMV2959 also reduced the fentanyl-seeking/relapse-like behaviour tested in rats on the 12th day of the forced abstinence period. Pretreatment with JMV2959 significantly and dose-dependently reduced the manifestation of fentanyl-CPP. The fentanyl-CPP development was reduced after the simultaneous administration of JMV2959 with fentanyl during conditioning. The JMV2959 significantly reduced the accumbens dopamine release induced by subcutaneous and intravenous fentanyl. Simultaneously, it affected the concentration of byproducts associated with dopamine metabolism in the NAC. Our findings suggest that GHS-R1A importantly participates in the rewarding/reinforcing effects of fentanyl.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a zvířata $7 D000818
650    _2
$a operantní podmiňování $x účinky léků $7 D003216
650    _2
$a dopamin $x metabolismus $7 D004298
650    _2
$a fentanyl $x aplikace a dávkování $x škodlivé účinky $7 D005283
650    _2
$a ghrelin $x metabolismus $7 D054439
650    _2
$a glycin $x analogy a deriváty $x farmakologie $7 D005998
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a narkotika $x aplikace a dávkování $x škodlivé účinky $7 D009294
650    _2
$a nucleus accumbens $x účinky léků $7 D009714
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory ghrelinu $x antagonisté a inhibitory $7 D054440
650    _2
$a autoaplikace $7 D012646
650    _2
$a triazoly $x farmakologie $7 D014230
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Puskina, Nina $u Department of Addictology, First Faculty of Medicine, Charles University, Czech Republic
700    1_
$a Havlickova, Tereza $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Czech Republic
700    1_
$a Lapka, Marek $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Czech Republic
700    1_
$a Syslova, Kamila $u Laboratory of Medicinal Diagnostics, Department of Organic Technology ICT, Czech Republic
700    1_
$a Pohorala, Veronika $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Czech Republic
700    1_
$a Charalambous, Chrysostomos $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Czech Republic
773    0_
$w MED00006247 $t Addiction biology $x 1369-1600 $g Roč. 25, č. 6 (2020), s. e12845
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31696597 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132924 $b ABA008
999    __
$a ok $b bmc $g 1715218 $s 1146937
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 25 $c 6 $d e12845 $e 20191106 $i 1369-1600 $m Addiction biology $n Addict Biol $x MED00006247
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options